The demand for Lipid-Lowering Agents in the EAEU region is driven by various factors, including changing lifestyles, increasing prevalence of cardiovascular diseases, and rising healthcare expenditure.
Customer preferences: Consumers in the EAEU region are increasingly becoming health-conscious and are taking proactive measures to prevent chronic illnesses such as heart diseases. This has led to a surge in demand for Lipid-Lowering Agents, which are used to lower cholesterol levels in the blood. Patients are becoming more informed about the benefits of these drugs and are willing to pay a premium for effective and safe products.
Trends in the market: The Lipid-Lowering Agents market in the EAEU region is experiencing steady growth due to the increasing prevalence of cardiovascular diseases. Countries such as Russia, Kazakhstan, and Belarus have a high burden of cardiovascular diseases, which has led to a rise in demand for these drugs. The market is also being driven by the introduction of new and innovative drugs that are more effective and have fewer side effects. The market players are investing heavily in research and development to bring new products to the market.
Local special circumstances: Russia is the largest market for Lipid-Lowering Agents in the EAEU region, accounting for a significant share of the market. The market is highly consolidated, with a few major players dominating the market. The regulatory environment is also stringent, which has led to a delay in the approval of new drugs. However, the government is taking steps to improve the regulatory environment and streamline the approval process, which is expected to boost the market growth.
Underlying macroeconomic factors: The Lipid-Lowering Agents market in the EAEU region is also influenced by macroeconomic factors such as rising healthcare expenditure, increasing disposable income, and changing lifestyles. The governments in the region are investing heavily in healthcare infrastructure, which has led to an increase in the availability of healthcare services. The rising disposable income has also led to an increase in healthcare spending, which has further boosted the market growth. The changing lifestyles, including unhealthy diets and lack of physical activity, have led to an increase in the prevalence of chronic diseases, which has further fueled the demand for Lipid-Lowering Agents.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
